Table 7. In vivo activity of Abbott quinobenoxazine 56 against systemic murine tumors.
| Tumor type | Treatment route and schedule | Best % TWIa | Best % ILSb | Cures (%) | Dose (mg/kg) |
|---|---|---|---|---|---|
| P388 | i.p. BID D1-9 | * | 85 | 10 | 10.0 |
| P388/ADR (MDR) | i.p. BID D1-9 | * | 50 | * | 10.0 |
| M5076 | i.p. BID D1-9 | 68 | 95 | 30 | 10.0 |
| i.v. Q4Dx3 | 99 | * | * | 40.0 | |
| C26 | i.p. QD D1-9 | 62 | 92 | 40 | 10.0 |
| i.v. Q4Dx3 | 95 | * | * | 40.0 | |
| B16 | i.p. BID D1-9 | 67 | * | * | 5.0 |
| i.v. Q4Dx3 | * | 13 | 19.6 | * | |
| Lewis lung | i.p. QD D1-9 | 65 | * | * | 2.5 |
| i.v. Q4Dx3 | 59 | 31 | * | 40.0 |
aTumor weight inhibition; bincreased life span; *data not reported.